First-in-human study of TK-positive oncolytic vaccinia virus delivered by adipose stromal vascular fraction cells
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
First-in-human study of TK-positive oncolytic vaccinia virus delivered by adipose stromal vascular fraction cells
Authors
Keywords
Clinical trial, Oncolytic vaccinia virus, Stromal vascular fraction, Immunotherapy of cancer
Journal
Journal of Translational Medicine
Volume 17, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2019-08-19
DOI
10.1186/s12967-019-2011-3
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Phase I study of oncolytic vaccinia virus GL-ONC1 in patients with peritoneal carcinomatosis
- (2018) Ulrich M. Lauer et al. CLINICAL CANCER RESEARCH
- International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study
- (2018) Franck Pagès et al. LANCET
- Turning cold tumours hot: oncolytic virotherapy gets up close and personal with other therapeutics at the 11th Oncolytic Virus Conference
- (2018) Arthur Dyer et al. CANCER GENE THERAPY
- The immunologic constant of rejection classification refines the prognostic value of conventional prognostic signatures in breast cancer
- (2018) François Bertucci et al. BRITISH JOURNAL OF CANCER
- Cancer immunotherapy: Opportunities and challenges in the rapidly evolving clinical landscape
- (2017) Leisha A. Emens et al. EUROPEAN JOURNAL OF CANCER
- IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
- (2017) Mark Ayers et al. JOURNAL OF CLINICAL INVESTIGATION
- Oncolytic virus-induced cell death and immunity: a match made in heaven?
- (2017) Jolien De Munck et al. JOURNAL OF LEUKOCYTE BIOLOGY
- Identification of genetic determinants of breast cancer immune phenotypes by integrative genome-scale analysis
- (2017) Wouter Hendrickx et al. OncoImmunology
- Phase 1 Study of Intravenous Oncolytic Poxvirus (vvDD) in Patients With Advanced Solid Cancers
- (2016) Stephanie Downs-Canner et al. MOLECULAR THERAPY
- The mechanisms of genetically modified vaccinia viruses for the treatment of cancer
- (2015) Artrish Jefferson et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Complement Inhibition Prevents Oncolytic Vaccinia Virus Neutralization in Immune Humans and Cynomolgus Macaques
- (2015) Laura Evgin et al. MOLECULAR THERAPY
- Localized Oncolytic Virotherapy Overcomes Systemic Tumor Resistance to Immune Checkpoint Blockade Immunotherapy
- (2014) D. Zamarin et al. Science Translational Medicine
- Combination immunotherapy with oncolytic vaccinia virus and checkpoint inhibitor following local tumor irradiation
- (2014) Boris Minev et al. Journal for ImmunoTherapy of Cancer
- Vaccinia viruses: vaccines against smallpox and vectors against infectious diseases and tumors
- (2011) Stephen R Walsh et al. Expert Review of Vaccines
- Oncolytic vaccinia virus: a theranostic agent for cancer
- (2010) Nanhai G Chen et al. Future Virology
- ACAM2000™: The new smallpox vaccine for United States Strategic National Stockpile
- (2010) Aysegul Nalca et al. Drug Design Development and Therapy
- Impaired interferon signaling is a common immune defect in human cancer
- (2009) R. J. Critchley-Thorne et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Real-time PCR assay to identify variants of Vaccinia virus: Implications for the diagnosis of bovine vaccinia in Brazil
- (2008) Giliane de Souza Trindade et al. JOURNAL OF VIROLOGICAL METHODS
- Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial
- (2008) Byeong-Ho Park et al. LANCET ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started